Current Developments in The Field of Biosimilars

Biologic products developed via rDNA technology as recombinant protein-based medicines that have been in clinical use since the early 1980s as original biopharmaceuticals have greatly contributed to the therapy of severe metabolic and degenerative diseases. The recent expiration of the data protection or patents for most of them created opportunities for the development of copy versions of original biopharmaceuticals with similar biologic activity (termed biosimilars). Production of these new products is expected to meet worldwide demand, promote market competition, maintain the incentives for innovation, and sustain the healthcare systems. The licensing of these products, however, relies on the experience gained with the original biopharmaceuticals.

  • Interchangeability of biosimilars
  • Improvements in uptake of biosimilars
  • Efficacy of biosimilars
  • Evolution of Biosimilars in Developed and Developing Countries
  • Scaling up considerations
  • Improving Biosimilar process capabilities

Related Conference of Current Developments in The Field of Biosimilars

February 28-March 01, 2019 ANA Crowne Plaza |

Global Pharmaceutical and Pharma Industry Conference

Osaka, Japan
March 18-19, 2019

13th International Conference on Biosimilars and Biologics

Amsterdam | Netherlands
July 26-27, 2019

13th Asian Biologics and Biosimilars Congress

Mercure Albert Park | Melbourne, Australia

Current Developments in The Field of Biosimilars Conference Speakers

Recommended Sessions

Related Journals

Are you interested in